Panelists discuss how AML treatment has entered an exciting era of personalized medicine with increasing oral options and ...

New developments in the complex and rapidly changing world of acute myeloid leukemia (AML) promise to improve health outcomes for people with the disease. They include: Advances in diagnostics ...

Midostaurin was granted a priority review for a new drug application by the FDA to treat a subset of patients with acute myeloid leukemia. Midostaurin (PKC412) was granted a priority review to a new ...

There is no standard treatment in acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) for patients who have a relapse following allogeneic hematopoietic cell transplantation. Patients who ...

Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing ...